According to a recent LinkedIn post from Francis Medical, the company is emphasizing clinical and procedural advantages of its Vanquish water vapor ablation system for prostate lesions. The post notes that the system is designed to treat lesions throughout the prostate, including the apex, anterior, and transition zones, via a transurethral approach using standard cystoscopy and TRUS.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post also highlights reported outcomes such as high patient satisfaction and low rates of urinary incontinence and erectile dysfunction, and it directs readers to VAPOR 2 Study results and safety information. For investors, this focus on broad anatomical applicability and quality-of-life outcomes suggests Francis Medical may be positioning Vanquish as a differentiated minimally invasive option in urology, which could support adoption, reimbursement discussions, and longer-term revenue potential in the prostate health market.